Jennifer Kuehn

Title: Innovations by Jennifer Kuehn in Autoimmune Disease Treatment

Introduction

Jennifer Kuehn is an accomplished inventor based in Frankfurt-am-Main, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of multispecific binding proteins aimed at treating autoimmune diseases. Her innovative work has garnered attention in the scientific community.

Latest Patents

Jennifer Kuehn holds a patent for CD28/OX40 bispecific antibodies. This patent describes multispecific binding proteins that include a first antigen binding domain (ABD) with binding specificity to CD28 and a second ABD with binding specificity to OX40. The patent also outlines methods for treating autoimmune diseases using these multispecific binding proteins. This invention represents a promising advancement in therapeutic options for patients suffering from autoimmune conditions.

Career Highlights

Jennifer Kuehn is currently employed at Sanofi, a global biopharmaceutical company. Her role at Sanofi allows her to work on cutting-edge research and development projects that aim to improve patient outcomes through innovative therapies. Her expertise in immunology and biotechnology has positioned her as a key contributor to the company's research initiatives.

Collaborations

Jennifer collaborates with notable colleagues such as Gerald Beste and Yanik Bruynooghe. These partnerships enhance the research efforts at Sanofi and contribute to the advancement of innovative treatments in the field of autoimmune diseases.

Conclusion

Jennifer Kuehn's work exemplifies the impact of innovation in biotechnology, particularly in the treatment of autoimmune diseases. Her patent for CD28/OX40 bispecific antibodies showcases her commitment to advancing medical science and improving patient care.